Publications by authors named "Corina Mogosan"
Article Synopsis
- - The research aimed to assess data collection practices for non-musculoskeletal manifestations (NMMs), comorbidities, and safety outcomes in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) across 17 European registries, emphasizing the need for international collaboration for better treatment strategies.
- - A comprehensive survey with over 4,400 questionnaire items examined how 58 defined conditions were recorded in each registry, focusing on recording methods and the ability to link data to national registries.
- - The study found that while many registries recorded a variety of conditions consistently, Nordic countries showed potential for data linkage but had limited recording practices, while other regions maintained thorough documentation, paving the way
In psoriatic arthritis (PsA), musculoskeletal ultrasound is a complementary tool to physical examination, useful even in patients in remission to detect subclinical activity. The objective of the study was to assess the ultrasound prevalence of active enthesitis and synovitis in patients who reached the therapeutic target. This cross-sectional study included patients with at least 6 months of therapy with a targeted synthetic or biological disease-modifying antirheumatic drug who were in treatment target (i.
View Article and Find Full Text PDFObjectives: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.
Methods: Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.
Sex differences in patient-reported outcomes and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors.
Rheumatology (Oxford)
July 2024
Article Synopsis
- The study aimed to explore sex differences in patient-reported outcomes (PROMs) among patients with axial spondyloarthritis (axSpA) starting their first tumor necrosis factor inhibitor (TNFi).
- Data from 15 registries were analyzed, focusing on changes in BASDAI and BASFI scores over 24 months using linear mixed models.
- Results indicated that women reported significantly worse outcomes than men, with the sex differences in scores nearly doubling after 6 months, and baseline characteristics such as HLA-B27 positivity and disease duration helped explain some but not all of the differences.
Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries.
Arthritis Care Res (Hoboken)
November 2024
Article Synopsis
- The study aimed to determine whether the modified 28-joint disease activity index (DAPSA28) or the 28-joint disease activity score with C-reactive protein (DAS28-CRP) is better for monitoring disease activity in psoriatic arthritis (PsA) when the full joint count is unavailable.
- Analysis of real-world data from over 3,000 European patients revealed that at the 6-month mark, DAPSA28 provided similar remission rates to DAPSA, but DAS28-CRP showed significantly higher rates of both remission and response.
- The results suggest that DAPSA28 is preferable to DAS28-CRP when conducting assessments without a full joint count due to the
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
J Rheumatol
April 2024
Objective: To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex, and age at disease onset.
Methods: Visual analog scale or numerical rating scale scores for pain, fatigue, patient global assessment (PtGA), and the Health Assessment Questionnaire-Disability Index (HAQ-DI) from 12,262 patients with PsA initiating a TNFi in 13 registries were pooled.
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network.
Arthritis Rheumatol
April 2024
Objective: Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi.
Methods: Data from patients with PsA across 13 European Spondyloarthritis Research Collaboration Network registries starting their first TNFi were pooled.
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe.
Lancet Reg Health Eur
October 2023
Article Synopsis
- This report compares treatment recommendations for two types of arthritis, PsA and axSpA, in different European countries.
- Rheumatologists from 15 countries answered a survey, showing that only a few countries fully followed the latest recommendations.
- The findings suggest that some countries might need to change their treatment guidelines to match the newer international ones better.
The current study aimed to evaluate rheumatoid arthritis (RA) patients with interstitial lung disease (ILD) in clinical practice and whether disease characteristics are associated with X-ray and high-resolution computed tomography (HR-CT) findings. Medical history of RA patients from a tertiary rheumatology clinic was retrieved from its electronic database starting from 1 January 2019 until the study date (8 August 2022) using International Classification of Disease version 10 codes for RA, ILD and exclusion criteria. The study included 78 RA patients (75.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare the effectiveness and safety of biosimilar adalimumab (bADA) with original adalimumab (oADA) in treating rheumatoid arthritis (RA) patients in Romania.
- It analyzed 441 RA patients from the Romanian Registry of Rheumatic Diseases, finding no significant differences in remission rates between the two treatments after six months.
- Adverse events were reported more frequently in patients using oADA (81.3%), with infections being the most common, but the overall efficacy and safety profile after six months was similar for both treatments.
Objective: The study aims to compare the efficacy and safety of biosimilar etanercept (SB4) to original etanercept (ETN) in a real-life national cohort of rheumatoid arthritis (RA).
Methods: Data from RA patients were retrieved electronically from the Romanian Registry of Rheumatic Diseases (RRBR), which contains all patients receiving biologics in the country.
Results: The study included 242 patients with efficacy and safety data after 6 months of treatment: 123 (50.
Rheumatoid arthritis (RA) is associated with increased costs generated by resource utilization and loss of work productivity. We have studied 206 RA patients and analyzed indirect costs of RA in Romania (estimated using the human capital approach) in comparison with reported data for other countries. Data were collected using self-reported questionnaires.
View Article and Find Full Text PDFIntroduction: The study aimed to evaluate the influence of socioeconomic factors on rheumatoid arthritis (RA) patients' access to biologics in Romania.
Method: Cross-sectional data were collected in January 2014 from the Romanian Registry of Rheumatic Diseases (RRRD) comprising all RA patients on biologics from 42 Romanian counties. "Territorial" access to biologics was defined by patients receiving biologics in their home county.
Background: rheumatoid arthritis (RA) is associated with the loss of overall functionality, which leads to substantial economic losses. Second line agents used in RA treatment require careful monitorization in terms of efficiency and tolerability.
Objective: trends, predictive factors and characteristics of clinical, biological and radiological RA monitorization in a cross sectional observational cohort study, conducted on over 206 patients in Romania, with a 12 months follow up (December 2007 - December 2008).
Background: Rheumatoid arthritis (RA) is associated with loss of overall functionality of the locomotion system and it is connected with substantial economic losses.
Objective: To describe the clinical characteristics and healthcare resource utilization characteristics and to analyze the correlations in a cross-sectional sample of 206 patients in Romania.
Method: RA cases have been enrolled from southern and western part of the country, covering a surface of 23 counties.